# Thyroid cancer: symptoms, treatment and survival > Source: World Aid Network — https://worldaidnetwork.org/cancer/thyroid-cancer > Last reviewed: 2026-06-19 ## In short Thyroid cancer starts in the thyroid, a small butterfly-shaped gland in the neck that controls how your body uses energy. The most common sign is a painless lump in the neck. The reassuring news is that most neck lumps are not cancer, and even when they are, thyroid cancer is one of the most curable cancers — over 95% of. One of the most curable cancers — usually starting as a painless neck lump. World Aid Network funds treatment for patients who cannot pay. ## At a glance - ~4,500: UK cases each year - Painless neck lump: Most common sign - Over 95%: 5-year survival - Surgery: Main treatment ## What is thyroid cancer? Thyroid cancer starts in the thyroid, a small butterfly-shaped gland in the neck that controls how your body uses energy. The most common sign is a painless lump in the neck. The reassuring news is that most neck lumps are not cancer, and even when they are, thyroid cancer is one of the most curable cancers — over 95% of. Thyroid cancer is the most common endocrine malignancy and one of the most curable cancers. Around 4,200 people in the UK are diagnosed every year, and it is approximately three times more common in women than men. For the most common types — papillary and follicular thyroid cancer — five-year survival rates exceed 95%, and many patients are effectively cured with surgery alone. The thyroid gland sits at the front of the neck and produces hormones that regulate metabolism, heart rate and body temperature. Most thyroid lumps (nodules) are benign, but any persistent neck lump should be assessed by a GP to exclude malignancy. This guide answers the twenty most commonly searched questions about thyroid cancer in the UK, drawing on NHS and WHO sources. Papillary thyroid carcinoma (PTC) is the most common type, accounting for approximately 80% of all thyroid cancers. It is slow-growing, spreads to cervical lymph nodes (but this does not significantly worsen prognosis) and is highly curable — five-year survival exceeds 98% for Stage I. Follicular thyroid carcinoma (FTC, approximately 10–15%) is also differentiated and well-treated, but spreads via the bloodstream rather than lymph nodes. Both PTC and FTC are classified as differentiated thyroid cancers (DTC) and respond well to radioiodine treatment. Medullary thyroid carcinoma (MTC, approximately 4%) arises from parafollicular C cells (calcitonin-producing cells) rather than follicular cells. It does not respond to radioiodine; approximately 25% are hereditary, arising in the context of MEN2 syndrome (multiple endocrine neoplasia type 2) caused by RET proto-oncogene mutations. Anaplastic thyroid carcinoma (undifferentiated, approximately 2%) is rare but extremely aggressive — most patients survive only months from diagnosis. It requires urgent specialist management. ## When should you see a doctor about thyroid cancer? Most of these symptoms have a less serious cause — but it is always worth getting them checked. See a GP if you notice a new or persistent change. If you feel very unwell, contact NHS 111 or seek urgent help. Take a note of how long the symptom has lasted and whether it is getting worse. You do not need every sign on a list to book an appointment. This guide is general information from World Aid Network, not a diagnosis and not UK NHS care. Only a clinician can assess you. - A painless lump in the front of the neck that is growing - A hoarse voice that does not get better - Difficulty swallowing or breathing - A swelling or lump in the neck that lasts more than a few weeks ## How is it diagnosed? A thyroid nodule is assessed with neck ultrasound, which characterises the nodule's features (size, echogenicity, vascularity, calcification, margins). The U1–U5 classification system guides management: U1 (normal) and U2 (benign) require no biopsy; U3 (indeterminate) and U4 (suspicious)/U5 (malignant) require fine needle aspiration cytology (FNA). FNA — a simple outpatient procedure using a fine needle to aspirate cells from the nodule — produces a Thy1–Thy5 cytological grading: Thy4 and Thy5 require surgical excision. Blood tests include thyroid function tests (TSH, T4, T3), calcitonin (elevated in MTC) and thyroglobulin (used for monitoring DTC after treatment, not for primary diagnosis). CT and MRI are used for staging and surgical planning. Radioiodine whole body scan is used after thyroidectomy in DTC to assess residual thyroid tissue and metastatic disease. ## What treatment is available? Surgical treatment is the cornerstone of thyroid cancer management. Total thyroidectomy is standard for most thyroid cancers; hemithyroidectomy (removal of one lobe) is appropriate for low-risk, small papillary or follicular cancers. Central neck dissection (removal of lymph nodes in the central compartment) and lateral neck dissection are performed when lymph node involvement is confirmed or suspected. After total thyroidectomy for differentiated thyroid cancer, radioiodine ablation (I-131) destroys residual thyroid tissue and micrometastases. Lifelong levothyroxine replacement is required after total thyroidectomy, usually at a TSH-suppressive dose to reduce stimulation of any residual DTC cells. For progressive, iodine-refractory DTC, targeted therapies — lenvatinib and sorafenib (NICE approved) — provide significant disease control. Vandetanib and cabozantinib are targeted therapies approved for MTC. ## What are the key takeaways? The most important points on thyroid cancer for patients, families and donors. - Thyroid cancer is one of the most curable cancers. Five-year survival exceeds 98% for papillary thyroid cancer Stage I and remains excellent for most differentiated thyroid cancers at all stages. - A painless lump in the front of the neck is the most common presenting symptom. Other symptoms include hoarse voice, difficulty swallowing, swollen lymph nodes in the neck and, rarely, breathlessness. - Most thyroid nodules are benign. Assessment with ultrasound and FNA biopsy (Thy1–Thy5 grading) determines which nodules require surgical excision. - Standard treatment is thyroidectomy followed by radioiodine ablation (I-131) for differentiated thyroid cancers and lifelong levothyroxine at TSH-suppressive doses. Lenvatinib/sorafenib are used for iodine-refractory advanced disease. - Medullary thyroid cancer (MTC) can be hereditary (MEN2 syndrome). All patients with MTC should have RET mutation testing. Family members of those with hereditary MTC should be tested and monitored. ## What will a donation for thyroid cancer treatment provide? A gift to World Aid Network's Cancer Emergency Appeal helps pay for diagnosis and treatment that a poor patient has been recommended but cannot afford. Typical partner costs start at £10 for tests and £50 for a chemotherapy session. Trustees direct gifts to the most urgent cases. This is treatment access, not laboratory research and not UK NHS care. Clinicians in partner hospitals decide the medical plan. We fund the bill in Pakistan, Indonesia and Malaysia. The Cancer Emergency Appeal funds all types of cancer. Trustees direct gifts to the most urgent hospital bills in Pakistan, Indonesia and Malaysia. - £10 — Diagnostic tests that help a partner oncologist confirm the next step - £25 — Cancer medication towards a treatment cycle a family cannot afford - £50 — One chemotherapy session for a patient who would otherwise be turned away - £100 — Surgical support or a fuller block of treatment costs ## How can I donate to help people with thyroid cancer? Donate by card on this page or at worldaidnetwork.org/donate and choose the Cancer Emergency Appeal. World Aid Network is a UK CIO with Charity Commission registration in progress; Gift Aid applies once registration is granted. If you need UK support as a patient or relative, see a GP, NHS 111, Macmillan or the specialist UK charity for this cancer. We fund treatment overseas; we are not a UK helpline. ## Frequently asked questions ### What is thyroid cancer? Thyroid cancer is a malignant tumour arising from the thyroid gland — the butterfly-shaped gland in the front of the neck that produces thyroid hormones. It is the most common endocrine malignancy, with approximately 4,200 UK diagnoses per year. It is three times more common in women than men. The most common type — papillary thyroid carcinoma — has a five-year survival rate exceeding 98% for early-stage disease, making it one of the most curable cancers. ### What are the symptoms of thyroid cancer? The most common presenting symptom is a painless lump or swelling in the front of the neck. Other symptoms include: a hoarse or changed voice (caused by pressure on the recurrent laryngeal nerve); difficulty swallowing (dysphagia); difficulty breathing or a sensation of pressure in the throat; swollen lymph nodes in the neck; and, rarely, neck pain radiating to the ears. Most thyroid lumps are benign thyroid nodules — but any persistent neck lump should be assessed by a GP to exclude malignancy. ### Is a thyroid nodule the same as thyroid cancer? No. Thyroid nodules are extremely common — approximately 50–70% of adults have a detectable thyroid nodule on ultrasound, and the vast majority are benign. Only approximately 5–15% of thyroid nodules assessed with FNA biopsy are found to be malignant. A thyroid nodule that is solid, hypoechoic, has irregular margins, contains microcalcifications or has associated lymph node changes on ultrasound is more suspicious and requires FNA biopsy. Many benign nodules require only ultrasound surveillance. ### What are the types of thyroid cancer? The four main types are: papillary thyroid carcinoma (PTC) — the most common (~80%), slow-growing, excellent prognosis; follicular thyroid carcinoma (FTC) — approximately 10–15%, also excellent prognosis; medullary thyroid carcinoma (MTC) — approximately 4%, arises from C cells, ~25% hereditary, does not respond to radioiodine; and anaplastic thyroid carcinoma — approximately 2%, extremely aggressive, median survival only weeks to months. Each type requires different treatment and has a different prognosis. ### What causes thyroid cancer? The cause of most thyroid cancers is unknown. Established risk factors include: ionising radiation exposure — particularly in childhood (e.g. previous radiotherapy to the head and neck, or the Chernobyl nuclear disaster which caused a marked increase in childhood thyroid cancer in affected regions); a family history of thyroid cancer or MEN2 syndrome; RET proto-oncogene mutations (hereditary MTC); female sex; being aged 35–55; and possibly iodine deficiency (associated with follicular carcinoma) or excess iodine (associated with papillary carcinoma in some populations). ### How is thyroid cancer diagnosed? A GP feeling a neck lump will order a thyroid ultrasound. Nodules scoring U3–U5 (indeterminate, suspicious or malignant features) are investigated with fine needle aspiration (FNA) cytology — a clinic procedure in which a thin needle withdraws cells from the nodule for microscopic examination (Thy1–Thy5 grading). Thy4 and Thy5 require surgical excision. Blood tests include TSH, T4 and calcitonin (for suspected MTC). CT or MRI assesses for lymph node involvement and tracheal invasion. ### What is FNA biopsy of the thyroid? Fine needle aspiration (FNA) biopsy is the standard method for investigating a suspicious thyroid nodule. A thin, fine needle is inserted into the nodule under ultrasound guidance to aspirate cells; no anaesthetic is required. The sample is analysed by a cytopathologist and graded Thy1 (non-diagnostic), Thy2 (non-neoplastic/benign), Thy3 (follicular lesion/neoplasm — indeterminate), Thy4 (suspicious of malignancy) or Thy5 (malignant). Thy4 and Thy5 trigger surgical referral. Thy3 often requires repeat sampling or diagnostic hemithyroidectomy. ### What is the treatment for thyroid cancer? Standard treatment for most differentiated thyroid cancers is thyroidectomy (total or hemithyroidectomy depending on risk), followed by radioiodine ablation (I-131) in moderate and high-risk cases to destroy residual thyroid tissue. Lifelong levothyroxine therapy maintains thyroid hormone levels and suppresses TSH, reducing stimulation of residual DTC cells. For locally advanced or metastatic iodine-refractory differentiated thyroid cancer, lenvatinib or sorafenib (NICE-approved targeted therapies) are used. MTC is treated with surgery; vandetanib and cabozantinib for advanced MTC. ### What is radioiodine treatment for thyroid cancer? Radioiodine (I-131) ablation is given after total thyroidectomy for differentiated thyroid cancers (papillary and follicular). The patient swallows a capsule or drink of radioactive iodine, which is selectively taken up by residual thyroid cells (including micrometastases) and destroys them with radiation. The procedure requires a period of isolation (usually 2–7 days in hospital or at home) to prevent irradiating others from excreted radioactivity. Radioiodine reduces recurrence risk and aids monitoring via thyroglobulin levels and whole-body scans. It is not effective for MTC or anaplastic carcinoma. ### Do I need levothyroxine after thyroid cancer surgery? Yes — if you have had a total thyroidectomy, your thyroid gland has been removed and you will need lifelong levothyroxine replacement to maintain normal metabolism. After thyroid cancer surgery, the dose is usually set at a TSH-suppressive level — slightly higher than standard replacement — to keep TSH low and reduce its stimulating effect on any residual thyroid cancer cells. Your endocrinologist will adjust the dose over time based on thyroglobulin levels, imaging and long-term recurrence risk. ### What is the survival rate for thyroid cancer? Five-year survival rates in England: papillary thyroid cancer Stage I — approximately 99%; all differentiated thyroid cancer (papillary and follicular) — approximately 95–98% five-year survival; medullary thyroid cancer — approximately 85–90% five-year survival. Anaplastic thyroid carcinoma has a very poor prognosis with median survival of three to five months from diagnosis. Overall, thyroid cancer has one of the best prognoses of any malignancy, largely because the majority are differentiated cancers diagnosed at an early stage. ### Is thyroid cancer hereditary? Most thyroid cancers are sporadic (not inherited). However, approximately 25% of medullary thyroid cancers (MTC) are hereditary — caused by germline RET proto-oncogene mutations — occurring in the context of MEN2A or MEN2B syndromes. All patients with MTC should have RET mutation testing, and first-degree relatives of those with hereditary MTC should be offered cascade genetic testing. Prophylactic thyroidectomy is recommended for RET mutation carriers before cancer develops. Family history also modestly increases the risk of differentiated thyroid cancer. ### What is MEN2 syndrome? Multiple endocrine neoplasia type 2 (MEN2) is a rare inherited syndrome caused by mutations in the RET gene, characterised by a high lifetime risk of medullary thyroid carcinoma. MEN2A also includes phaeochromocytoma (adrenal tumour) and primary hyperparathyroidism. MEN2B includes phaeochromocytoma, mucosal neuromas and marfanoid habitus. The RET mutation determines the specific disease variant and age of onset. Prophylactic thyroidectomy is offered to known RET mutation carriers — ideally before the age at which MTC typically develops in that mutation subtype. ### Can thyroid cancer spread? Papillary thyroid cancer commonly spreads to regional cervical lymph nodes — but this does not significantly worsen prognosis in well-differentiated papillary carcinoma. Distant metastasis (to lung or bone) is more common with follicular carcinoma and worsens prognosis, though differentiated thyroid cancer metastases may still respond to radioiodine. Medullary carcinoma spreads to lymph nodes and liver. Anaplastic carcinoma is extremely aggressive, with rapid local invasion and distant spread. ### Can I live normally after thyroid cancer treatment? The vast majority of people treated for differentiated thyroid cancer live a full, normal life after treatment. Long-term levothyroxine therapy is taken once daily and is well-tolerated. Regular follow-up — typically annual thyroglobulin measurement, neck ultrasound and periodic radioiodine whole-body scanning — monitors for recurrence. Long-term recurrence rates for well-differentiated thyroid cancer treated with total thyroidectomy and radioiodine ablation are low. Most patients are discharged from specialist follow-up after several years if thyroglobulin remains undetectable. ### Can thyroid cancer come back after treatment? Recurrence rates for differentiated thyroid cancer are relatively low with appropriate primary treatment (thyroidectomy ± radioiodine) — approximately 5–10% at 10 years for papillary carcinoma. Recurrence most commonly occurs in the thyroid bed or cervical lymph nodes. Rising thyroglobulin levels during follow-up (in the context of undetectable TSH-stimulated thyroglobulin at completion of treatment) is an early indicator of recurrence. Radioiodine-sensitive recurrences are treated with further radioiodine; iodine-refractory progressive disease is treated with lenvatinib or sorafenib. ### What targeted therapies are available for thyroid cancer? For iodine-refractory locally advanced or metastatic differentiated thyroid cancer: lenvatinib (first-line, NICE-approved) and sorafenib (second-line) are multi-kinase inhibitors that significantly prolong progression-free survival. For advanced medullary thyroid cancer: vandetanib and cabozantinib are RET/VEGFR inhibitors approved by NICE. For RET-fusion-positive or RET-mutated tumours, pralsetinib and selpercatinib are highly selective RET inhibitors with strong response rates, now available through NHS England Genomic Medicine. ### How does thyroid cancer affect people in developing countries? In low-income countries, thyroid cancer is frequently diagnosed at an advanced stage due to limited access to neck ultrasound, FNA biopsy and specialist endocrinology. Radioiodine facilities are scarce and unavailable to most rural poor patients. Levothyroxine — while inexpensive — is not consistently available in many settings. World Aid Network funds cancer treatment through locally-licensed oncologists, supporting access to cancer care that would otherwise be entirely inaccessible to poor patients. ## How you can help World Aid Network funds cancer treatment for poor patients in Pakistan, Indonesia and Malaysia through locally licensed oncologists. Donate at https://worldaidnetwork.org/cancer/thyroid-cancer or https://worldaidnetwork.org/donate?cause=cancer-treatment&appeal=cancer-emergency ## Sources - NHS — Cancer: https://www.nhs.uk/conditions/cancer/ - Cancer Research UK --- This is general information, not medical advice, published by World Aid Network. Always consult a qualified clinician about your own health.